Ann: CEO Presentation to Bioshares Conference, page-51

Why is FTT not yet able to build material value?
Why are the investment speculators unwilling to make a bet?
Why is big-pharma ignoring this 'blockbuster'?

By now it is most likely well known - in an informal way through the usual investigative activities of big-pharma and professional speculators - which way the trial outcome is going to. Double-blinded or not, patients are people and people talk and others listen. And if this involves a potentially disruptive technology there are probably many big ears listening.

Could be some hidden strings tying FTT/TIS down we know nothing about.
As example, the xfer of IP from QUT(BlueBox) to TIS/FTT was announced and, I assume, did actually happen.
But, and that's a big but, has QUT actually given the stuff up without any strings (like caveats or prid-pro-quo's) attached to it?
It is my opinion that a commercial entity, like QUT(BlueBox), acting in such a benevolent way by voluntarily releasing (potentially a gold mine) IP and not asking for any return-in-kind is very rare indeed.
If there are any strings attached then the building of material value at this stage is not going to happen.
And it may even be a big hurdle for the future buildup too - even assuming a positive trial outcome.